《新股消息》風華秋實再遞上市申請 藝人鹿(日含)貢獻上半年收入25.2%
內地音樂娛樂服務供應商風華秋實第五度向聯交所遞交主板上市申請,獨家保薦人為同人融資。
風華秋實主要從事音樂版權授權、音樂錄製、演唱會主辦及製作以及藝人管理等業務,截至今年10月,旗下音樂庫共有約829件音樂作品,現正管理11名音樂藝人及10名練習生藝人。
初步招股資料顯示,公司對核心藝人鹿(日含)有所倚賴,於2018年至2021年期間鹿(日含)分別為公司貢獻總收入約70.6%、25.5、21.2及9.3%,於今年上半年則貢獻約25.2%收入。
截至上半年,公司錄收入4,223.9萬元人民幣(下同),按年升近1.77倍。期內錄純利332萬元,對比去年同期虧損669.1萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.